Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

RMD Open. 2022 May;8(1):e002323. doi: 10.1136/rmdopen-2022-002323.

Filippo Fagni^{1

2}, Katja Schmidt^{1

2}, Daniela Bohr^{1

2}, Larissa Valor-Méndez^{1

2}, Fabian Hartmann^{1

2}, Koray Tascilar^{1

2}, Karin Manger³, Bernhard Manger^{1

2}, Arnd Kleyer^{1

2}, David Simon^{1

2}, Georg Schett^{1

2}, Thomas Harrer^{4

2}

¹ Department of Internal Medicine 3, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
² Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
³ Rheumatology Practice Bamberg, Bamberg, Germany.
⁴ Department of Internal Medicine 3, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany Thomas.Harrer@uk-erlangen.de.

No abstract available

Keywords: Autoimmune Diseases; COVID-19; Epidemiology; Rituximab; Vaccination.

Publication types